Skip to content | Change text size
 

Harald Schmidt

Harald Schmidt, born 1959, is Head of Pharmacology and directs the Centre for Vascular Health at Monash University, Melbourne, Australia. He graduated in both Pharmacy and Medicine before specialising in Clinical and Experimental Pharmacology. In his first postdoc, he discovered the precursor role of L-arginine for endogenous NO. In the early 90’s he continued this work in Chicago with the 1998 Nobel laureate, Ferid Murad. Back in Germany, he joined a Clinical Centre for Research Excellence at the University of Würzburg. Based on his IP, he founded and led as CEO the spin-off, vasopharm, who’s NOS inhibitors now enter the clinic. Since 2000, as head of Pharmacology in Gießen and co-chair of a collaborative research centre, he focuses on novel cardiovascular disease mechanisms including oxidative stress, and since 2005, at Monash, also on proteome-based diagnostics, molecular imaging and mechanisms-based drugs. He organises several international conferences and edits a major German textbook in Pharmacology.

Ten Career-best Publications

  1. Schmidt H.H.H.W., Pollock J. S., Nakane M., Gorsky L. D., Förstermann U. and Murad F.: Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc. Natl. Acad. Sci. U.S.A. 88: 365-369, 1991.
  2. Wilcox C. S., Welch W. J., Murad F., Gross S. S., Taylor G., Levi R. and Schmidt, H.H.H.W.: Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc. Natl. Acad. Sci. U.S.A. 89: 11993-11997, 1992.
  3. Schmidt H.H.H.W., Warner T. D., Ishii K., Sheng H. and Murad F.: Insulin-secretion from pancreatic B-cells caused by L-arginine-derived nitrogen oxides. Science 255: 721-723, 1992; Response ibid. 258: 1376-1378, 1992.
  4. Koch K.-W., Lambrecht H.-G., Haberecht M., Redburn D. and Schmidt H.H.H.W.: Functional coupling of a Ca2+/calmodulin dependent nitric oxide synthase and a soluble guanylyl cyclase in vertebrate photoreceptor cells. EMBO J. 13: 3312-3320, 1994.
  5. Schmidt H.H.H.W. and Walter U.: NO at work. Cell 78: 919-925, 1994.
  6. Schmidt H.H.H.W., Hofmann H., Schindler U., Shutenko Z., Cunningham D. and Feelisch M.: No NO from NO synthase. Proc. Natl. Acad. Sci. U.S.A. 93: 13712-13717, 1996.
  7. Zabel U., Kleinschnitz C., Smolenski A., Nedvetsky P., Kugler P., Walter U., Schnitzer J.E. and Schmidt H.H.H.W.: Calcium-dependent membrane association sensitises soluble guanylyl cyclase to NO. Nature Cell Biol 4: 307-311, 2002.
  8. Nedvetsky P.I., Sessa W.C. and Schmidt H.H.H.W.: There's NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling. Proc. Natl. Acad. Sci. U.S.A. 99: 16510-16512, 2002
  9. Melichar V.O., Behr-Roussel D., Zabel U., Uttenthal L.O., Rodrigo J., Rupin A., Verbeuren T.J., Kumar A. and Schmidt H.H.H.W.: Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 101: 16671-16676, 2004.
  10. Evgenov O.V., Pacher P., Schmidt P.M., Haskó G., Schmidt H.H.H.W. and Stasch J.P. Nitric oxide-independent stimulators and activators of soluble guanylyl cyclase. Nature Reviews Drug Discovery 5: 755-768, 2006.